They then went on to show that loss of TSC1 leads to reduced acetylation of HSP90 at K407/K419, which leads to decreased binding by ganetespib; and that inhibition of histone deacetylases with concurrent ganetespib treatment led to enhanced growth suppression of RT4, a TSC1 null bladder cancer cell line [66]. The gene discussed is TSC1; the disease is urinary bladder carcinoma.